ESMO Deep Dive: Upper Digestive Cancers – Oesophageal Cancer: from Molecule to Medicine

It is with great pleasure that we invite you to participate in the ESMO Deep Dive Webinar on oesophageal cancer, elaborating the facts from molecule to medicine.

This webinar is developed with the aim to analyse in detail the molecular alterations in patients with oesophageal adenocarcinomas; identify key pathways and targets explored in clinical trials for patients with advanced disease; discuss key questions that will challenge this field in the near future; further describe how new advances in radiation delivery techniques can improve tumour targeting, sparing normal tissue and enhancing immune response, and discuss the emerging role of proton beam therapy in the curative treatment of oesophageal cancer.

I am delighted to announce the distinguished speakers who will join me in this webinar. We will begin with a lecture on dissecting the molecular landscape of oesophageal adenocarcinomas to optimise outcomes. This will be followed by a presentation on the new era of chemotherapy and multimodal therapy for patients with oesophageal cancer. Finally, we will review whether radiation therapy is the ideal partner for improved outcomes and discuss in particular the novelties of particle therapy. The lectures will be followed by a live discussion with the full speaker panel.

The programme is designed to provide an overview of the latest understanding of molecular alterations, key pathways, targets, and multimodal management of patients with oesophageal cancer, offer expert opinion exchange and provide some important considerations in this field. We strongly encourage and invite you to register and join us all in this new ESMO activity.

Thierry Alcindor
Director, Division of Medical Oncology, McGill University Health Centre, Montreal, Canada
Associate Director, Clinical Trials in Oncology, McGill University Health Centre, Montreal, Canada
Associate Professor, McGill University, Montreal, Canada

AND

Elizabeth Smyth
Consultant, Gastrointestinal Oncology, Addenbrooke’s Hospital, Cambridge, United Kingdom